Micronase
Designed to target blood glucose levels utilized to support type 2 diabetes management.
Strengths: 2.5 · 5mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Daonil
- Therapeutic class
Sulfonylurea
- Pharmacological class
Sulfonylurea
- Contraindications
type 1 diabetes; diabetic ketoacidosis
- Precautions and warnings
risk of hypoglycaemia; take with meals
- Minor side effects
nausea; weight gain
- Moderate side effects
dizziness; skin rash
- Serious side effects
hypoglycaemic coma — requires immediate medical attention
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Sanofi
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store at room temperature.
- Drug interactions
alcohol; beta blockers
- Pregnancy and breastfeeding
Not recommended during pregnancy.
Patient summary
Designed to target blood glucose levels utilized to support type 2 diabetes management.
Mechanism of action
Increases insulin secretion from the pancreas by closing ATP-sensitive potassium channels in beta cells. This helps lower blood sugar levels in patients with type 2 diabetes.
Micronase
Designed to target blood glucose levels utilized to support type 2 diabetes management.
Editorial Notes
- Active ingredient(s): Glyburide
- Listed indication(s): Type 2 Diabetes Mellitus
Usually available as
- 360 tablets - 2.5 mg59-2-5-mg-3530
- 360 tablets - 5 mg59-5-mg-3536